SK bioscience strengthens partnership with Novavax

9 August 2023

South Korean vaccine developer SK bioscience’s (KRX: 302440) shares were up 4.6% at 84,500 won, after it announced its decision to make an equity investment of around $85 million in US biotech Novavax (Nasdaq: NVAX), which is advancing protein-based vaccines with its novel Matrix-M adjuvant, securing 6.5 million shares of common stock (a 7% stake) through a private placement. Novavax shares edged up 3.3% to $7.47 pre-market.

SK bioscience's strategic equity investment comes at a time when the two companies aim to transition from a CMO/CDMO partnership formed during the pandemic to a long-term synergistic relationship in the endemic era.

Additionally, SK bioscience and Novavax have extended their current license agreement, adding Novavax’s updated COVID-19 vaccine, which is currently under development for annual vaccination.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK